Schopfer K, Miebach E, Beck M, Pitz S. Lysosomal storage diseases: update and new therapeutic options. Klin Monbl Augenheilkd. 2011;228(2):144–60. https://doi.org/10.1055/s-0028-1109958.
Article CAS PubMed Google Scholar
Parkinson-Lawrence EJ, Shandala T, Prodoehl M, et al. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology. 2010;25:102–15. https://doi.org/10.1152/physiol.00041.2009.
Article CAS PubMed Google Scholar
Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. 2012;13:307–35. https://doi.org/10.1146/annurev-genom-090711-163739.
Article CAS PubMed Google Scholar
Scarpa M, Bellettato CM, Lampe C, Begley DJ. Neuronopathic lysosomal storage disorders: approaches to treat the central nervous system. Best Pract Res Clin Endocrinol Metab. 2015;29:159–71. https://doi.org/10.1016/j.beem.2014.12.001.
Article CAS PubMed Google Scholar
Tokic V, Barisic I, Huzjak N, et al. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr. 2007;166:727–32. https://doi.org/10.1007/s00431-006-0316-8.
Lim-Melia ER, Kronn DF. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009;38(8):448–55. https://doi.org/10.3928/00904481-20090723-09.
Beck M. Therapy for lysosomal storage disorders. IUBMB Life. 2010;62(1):33–40. https://doi.org/10.1002/iub.284.
Article CAS PubMed Google Scholar
Al Sawaf S, Mayatepek E, Hoffmann B. Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J Inherit Metab Dis. 2008;31:473–80. https://doi.org/10.1007/s10545-008-0878-x.
Article CAS PubMed Google Scholar
Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124(6):e1228–39. https://doi.org/10.1542/peds.2008-0999.
Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014;39:215–24. https://doi.org/10.1111/jcpt.12136.
Article CAS PubMed Google Scholar
Patel MM, Patel BM. Crossing the blood–brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109–33. https://doi.org/10.1007/s40263-016-0405-9.
Article CAS PubMed Google Scholar
Giugliani R, Dalla Corte A, Poswar F, et al. Intrathecal/intracerebroventricular enzyme replacement therapy for the mucopolysaccharidoses: efficacy, safety, and prospects. Expert Opin Orphan Drugs. 2018;6(7):403–11. https://doi.org/10.1080/21678707.2018.1487838.
Sato Y, Okuyama T. Novel enzyme replacement therapies for neuropathic mucopolysaccharidoses. Int J Mol Sci. 2020;21(2):400. https://doi.org/10.3390/ijms21020400.
Article CAS PubMed PubMed Central Google Scholar
Pardridge WM. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem. 2008;19(7):1327–38. https://doi.org/10.1021/bc800148t.
Article CAS PubMed Google Scholar
Lu JZ, Hui EK-W, Boado RJ, Pardridge WM. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug Chem. 2010;21:151–6. https://doi.org/10.1021/bc900382q.
Article CAS PubMed Google Scholar
Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol. 1999;5(6):556–69. https://doi.org/10.3109/13550289909021285.
Article CAS PubMed Google Scholar
Pardridge WM. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015;12(2):207–22. https://doi.org/10.1517/17425247.2014.952627.
Article CAS PubMed Google Scholar
Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng. 2007;96(2):381–91. https://doi.org/10.1002/bit.21120.
Article CAS PubMed Google Scholar
Sonoda H, Morimoto H, Yoden E, et al. A blood–brain–barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther. 2018;26(5):1366–74. https://doi.org/10.1016/j.ymthe.2018.02.032.
Article CAS PubMed PubMed Central Google Scholar
Morimoto H, Kida S, Yoden E, et al. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol Ther. 2021;29(5):1853–61. https://doi.org/10.1016/j.ymthe.2021.01.027.
Article CAS PubMed PubMed Central Google Scholar
Okuyama T, Eto Y, Sakai N, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial. Mol Ther. 2019;27:456–64. https://doi.org/10.1016/j.ymthe.2018.12.005.
Article CAS PubMed Google Scholar
Giugliani R, Martins AM, So S, et al. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil. Mol Ther. 2021;29(7):2378–86. https://doi.org/10.1016/j.ymthe.2021.03.019.
Article CAS PubMed PubMed Central Google Scholar
Okuyama T, Eto Y, Sakai N, et al. A phase 2/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol Ther. 2021;29(2):671–9. https://doi.org/10.1016/j.ymthe.2020.09.039.
Article CAS PubMed Google Scholar
Denali Therapeutics. Denali Therapeutics announces new interim data from phase 1/2 study of DNL310 (ETV:IDS) in MPS II (Hunter syndrome) at SSIEM 2022. News release. August 31, 2022. Available from: https://www.globenewswire.com/news-release/2022/08/31/2507598/0/en/Denali-Therapeutics-Announces-New-Interim-Data-from-Phase-1-2-Study-of-DNL310-ETV-IDS-in-MPS-II-Hunter-Syndrome-at-SSIEM-2022.html. Accessed 31 Aug 2022.
Ullman JC, Arguello A, Getz JA, et al. Brain delivery and activity of a lysosomal enzyme using a blood–brain barrier transport vehicle in mice. Sci Transl Med. 2020;12(545): eaay1163. https://doi.org/10.1126/scitranslmed.aay1163.
Article CAS PubMed Google Scholar
Arguello A, Meisner R, Thomsen ER, et al. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome. JCI Insight. 2021;6(19): e145445. https://doi.org/10.1172/jci.insight.145445.
Article PubMed PubMed Central Google Scholar
Boado RJ, Hui EKW, Lu JZ, Sumbria RK, Pardridge WM. Blood–brain barrier molecular Trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem. 2013;24(10):1741–9. https://doi.org/10.1021/bc400319d.
Article CAS PubMed Google Scholar
ArmaGen Technologies. Pipeline-chart. Available from: http://armagen.com/our-pipeline/pipeline-chart. Accessed 10 Jan 2023.
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7. https://doi.org/10.1016/0003-9861(59)90090-6.
Article CAS PubMed Google Scholar
Simpson RJ. Proteins and proteomics: a laboratory manual. Cold Spring Harbor: CSHL Press; 2003. (ISBN 0 87969 554).
Agilent. N-glycan preparation with InstantAB Kit user manual. Available from: https://www.agilent.com/cs/library/usermanuals/public/TDW-GP96NG-LB%20GlykoPrep%20Rapid%20N-Glycan%20Preparation%20with%20InstantAB%20090414AL.pdf. Accessed 1 Sep 2021.
Voznyi YV, Keulemans JLM, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inhert Metab Dis. 2001;24(6):675–80. https://doi.org/10.1023/a:1012763026526.
Tolun AA, Graham C, Shi Q, et al. A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots. Mol Genet Metab. 2012;105(3):519–21. https://doi.org/10.1016/j.ymgme.2011.12.011.
Article CAS PubMed Google Scholar
Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2):167–74. https://doi.org/10.1038/jhg.2016.133.
Article CAS PubMed Google Scholar
Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31(4):309–15. https://doi.org/10.1007/s10719-014-9523-0.
Article CAS PubMed Google Scholar
Dierks T, Schmidt B, von Figura K. Conversion of cysteine to formylglycine: a protein modification in the endoplasmic reticulum. Proc Natl Acad Sci USA. 1997;94(22):11963–8. https://doi.org/10.1073/pnas.94.22.11963.
Article CAS PubMed PubMed Central Google Scholar
Millat G, Froissart R, Maire I, Bozon D. Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue. Biochem J. 1997;326:243–7. https://doi.org/10.1042/bj3260243.
Article CAS PubMed PubMed Central Google Scholar
Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–37. https://doi.org/10.1016/j.ymgme.2006.09.001.
留言 (0)